ArticleSkin health and disease2026
Living with melanoma: a study protocol for the design and participatory development of a survivorship care programme for people with metastatic melanoma.
Article in Skin health and disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Survivorship care for melanoma patients: a scoping review.Journal of cancer survivorship : research and practice · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The growing number of people living with and beyond melanoma report unmet needs in survivorship care. To optimize melanoma survivorship care, it is critical to consider not only the perspectives of survivors of melanoma and their relatives, but also those of oncology healthcare professionals. The aim of this study is to develop an innovative survivorship care programme for people living with and beyond metastatic melanoma. Methods: The study follows the UK Medical Research Council framework and the intervention mapping approach. It also integrates the perspectives of all relevant stakeholders, from survivors of melanoma and their families to healthcare professionals. The development process (phase A) includes a scoping review and a qualitative study with interviews and focus groups. Stakeholder knowledge will be integrated through a participatory process involving patients, relatives, physicians, psycho-oncologists, nurses, epidemiologists and health services researchers. Discussion: Using different methodological approaches, we hope to gain insight into the needs of survivors of melanoma and develop a theory- and evidence-based survivorship care programme. The planned study will provide a patient-centred intervention to improve health-related outcomes for people with metastatic melanoma in general and to promote health literacy and quality of life for those affected. The subsequent feasibility and pilot study, including a structure and process evaluation (phase B), will provide an initial opportunity to determine the feasibility of a randomized controlled trial and of the survivorship care programme itself, in preparation for further effectiveness studies. Protocol registration: We set up an OSF project (https://doi.org/10.17605/OSF.IO/DV7MH) for the LeMela project. In addition, we have pre-registered a short protocol at OSF (https://doi.org/10.17605/OSF.IO/QVRXD).
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.